JBIO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Jade Biosciences Inc (JBIO) is not a strong buy at the moment for a beginner investor with a long-term strategy. While analysts have a positive outlook with a $25 price target, the lack of significant trading trends, neutral technical indicators, and weak financial performance make it prudent to hold off on investing until more positive catalysts emerge.
The MACD is below 0 and negatively contracting (-0.084), indicating a weak momentum. RSI is neutral at 51.685, and moving averages are converging, showing no clear trend. The price is near the pivot level of 14.649, with resistance at 15.922 and support at 13.375. Overall, the technical indicators suggest a neutral trend.
Analysts have initiated coverage with a Buy rating and a $25 price target, citing strong potential in the autoimmune space with projected revenues of $926M by 2037 for JADE101.
No significant news or trading trends. Financial performance is weak, with no revenue growth, a net loss of -$25.18M in Q3 2025, and a significant EPS decline (-96.75% YoY). Technical indicators are neutral, and there is no recent congress trading data.
In Q3 2025, revenue remained at $0 with no YoY growth. Net income improved by 55.05% YoY but remains negative at -$25.18M. EPS dropped significantly by -96.75% YoY to -0.64, indicating poor profitability.
H.C. Wainwright initiated coverage with a Buy rating and a $25 price target, highlighting JBIO's potential leadership in the autoimmune space.
